TBE antigens for research and IVD manufacturing applications

May 31, 2019

BINDING SITE’s IMMUNOLOGICALS GROUP announced the addition of two new native Tick-Borne Encephalitis (TBE) viral antigens to its broad offering of products for in-vitro diagnostic (IVD) manufacturing and research applications. Both the Standard version of the antigen, as well as the Premium version, have been conceived for use as a principle component within enzyme immunoassay (EIA) testing procedures.

TBE is caused by the tick-borne encephalitis virus, a human pathogenic species among the flaviviruses, and most often manifests as meningitis, encephalitis, or meningoencephalitis. The disease typically follows an incubation period of eight days after the initial bite and displays such non-specific symptoms as mild fever, malaise, headache, nausea and vomiting, after which the patient may develop the neurological symptoms. The number of reported cases has been increasing in most countries and TBE is posing a concerning health challenge to Europe, as the number of reported human cases of TBE have increased by almost 400 percent over the last three decades.

Both of the antigens offered exhibit exceptional purity levels as a result of unique manufacturing techniques, while also demonstrating exceptional lot-to-lot consistencies. They all feature an outstanding shelf life stability claim of ten years from the date of manufacture and are offered in a standard-sized 1.0mg filled vial, with larger, bulk packaging configurations also available. Test samples for initial evaluation procedures are also available upon request.

Visit Binding Site for more information